Pacira Biosciences CFO cross sells $626k in shares
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pacira Pharmaceuticals Inc (PCRX)
Assess today's live Pacira Pharmaceuticals Inc (PCRX) share price, performance and insights using our live NASDAQ: PCRX stock exchange data.
Analyse the historical data and Pacira Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Pacira share price buy/sell indicators using real-time data (or discuss the Pacira (PCRX) stock price today with other investors in the Pacira NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ PCRX share price (ISIN: US6951271005) to enhance your trading decisions with our free investment tools and resources.
What Is the Pacira Pharmaceuticals Inc Share Price Today?
The Pacira share price today is 25.74.
What Is the Stock Symbol for Pacira Pharmaceuticals Inc
The stock symbol (or 'ticker') for Pacira Pharmaceuticals Inc is "PCRX."
What Stock Exchange Does Pacira Pharmaceuticals Inc Trade On?
Pacira Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Pacira Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Pacira Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Pacira Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Pacira share price buy/sell indicators using real-time data (or discuss the Pacira (PCRX) stock price today with other investors in the Pacira NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ PCRX share price (ISIN: US6951271005) to enhance your trading decisions with our free investment tools and resources.
What Is the Pacira Pharmaceuticals Inc Share Price Today?
The Pacira share price today is 25.74.
What Is the Stock Symbol for Pacira Pharmaceuticals Inc
The stock symbol (or 'ticker') for Pacira Pharmaceuticals Inc is "PCRX."
What Stock Exchange Does Pacira Pharmaceuticals Inc Trade On?
Pacira Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Pacira Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Pacira Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.58
26.33
52 wk Range
18.17
27.64
PCRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
25.5826.33
52 wk Range
18.1727.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PCRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
29.71
Upside
+15.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Management has been aggressively buying back shares
- Form 144 Pacira BioSciences For: 10 December
- Investing.com
- Pacira Biosciences CFO cross sells $626k in shares
- Investing.com
- Form 144 Pacira BioSciences For: 10 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Pacira Company Profile
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Pacira Pharmaceuticals Inc SWOT Analysis
Patent Peril | Explore Pacira's battle against generic competition as legal challenges threaten its flagship product Exparel, potentially eroding market share and revenues |
NOPAIN, Big Gain? | Delve into Pacira's NOPAIN initiative and new partnerships, offering hope for growth amid challenges in the non-opioid pain management market |
Outpatient Opportunity | Learn how recent CMS rule changes could boost Pacira's Exparel and iovera adoption in outpatient settings, expanding market reach |
Financial Fortitude | Analysts set price targets ranging from $14 to $37, with Pacira's strong margins and cash flow suggesting resilience despite market headwinds |
Pacira Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Pacira BioSciences reported Q3 2025 revenue growth with Exparel sales reaching $139.9 million, though stock fell 3.41% after missing EPS forecasts.
- Non-GAAP gross margin improved to 82% from 78%, with strong performance across product lines including ZILRETTA ($29.0M) and iovera ($6.5M).
- The company completed $50 million in share repurchases while maintaining $246 million in cash and investments.
- Management provided 2025 revenue guidance of $725-735 million, targeting a five-year double-digit revenue CAGR.
- Strategic initiatives include advancing gene therapy pipeline and expanding the Johnson & Johnson MedTech partnership for ZILRETTA.
Last Updated: 06/11/2025, 22:46
Read Full TranscriptCompare PCRX to Peers and Sector
Metrics to compare | PCRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 51.7x | −5.8x | −0.6x | |
PEG Ratio | 0.42 | 0.09 | 0.00 | |
Price/Book | 1.5x | −86.9x | 2.6x | |
Price / LTM Sales | 1.5x | 8.6x | 3.2x | |
Upside (Analyst Target) | 8.8% | 51.4% | 41.8% | |
Fair Value Upside | Unlock | 12.6% | 5.1% | Unlock |
Analyst Ratings
4 Buy
2 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 29.71
(+15.44% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
0.70 / 0.65
Revenue / Forecast
179.50M / 182.29M
People Also Watch
FAQ
What Is the Pacira (PCRX) Share Price Today?
The live Pacira share price today is 25.74
What Stock Exchange Does Pacira (PCRX) Trade On?
Pacira is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Pacira?
The stock symbol (also called a 'ticker') for Pacira is "PCRX."
What Is the Current Pacira Market Cap?
As of today, Pacira market capitalisation is 1.11B.
What Is Pacira's (PCRX) Earnings Per Share (TTM)?
The Pacira EPS is currently 0.47 (Trailing Twelve Months).
When Is the Next Pacira Earnings Date?
Pacira's next earnings report will be released on 19 Feb 2026.
Is PCRX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Pacira moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pacira Stock Split?
Pacira has split 0 times. (See the PCRX stock split history page for full effective split date and price information.)
How Many Employees Does Pacira Have?
Pacira has 789 employees.
What is the current trading status of Pacira (PCRX)?
As of 24 Dec 2025, Pacira (PCRX) is trading at a price of 25.74, with a previous close of 26.02. The stock has fluctuated within a day range of 25.58 to 26.33, while its 52-week range spans from 18.17 to 27.64.
What Is Pacira (PCRX) Price Target According to Analysts?
The average 12-month price target for Pacira is USD29.71429, with a high estimate of USD38 and a low estimate of USD23. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +15.44% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.